期刊
EMERGING INFECTIOUS DISEASES
卷 24, 期 2, 页码 275-283出版社
CENTERS DISEASE CONTROL & PREVENTION
DOI: 10.3201/eid2402.171268
关键词
-
资金
- Japan Agency for Medical Research and Development [16fk0108311j0403]
- Pfizer Inc.
- Daiichi-Sankyo
- Merck Co., Inc.
- Japan Society for the Promotion of Science [17K10023]
- Pfizer
- Grants-in-Aid for Scientific Research [17K10023] Funding Source: KAKEN
After the introduction of pneumococcal conjugate vaccines, the incidence of pneumococcal infections due to meropenem-resistant serotype 15A-ST63 strains increased in Japan. By using whole-genome sequencing and comparing sequences with those of clones from the United Kingdom, the United States, and Canada, we clarified the traits of the serotype 15A-ST63 clone. Our analysis revealed that the meropenem-resistant serotype 15A-ST63 strains from Japan originated from meropenem-susceptible strains from Japan. Recombination site prediction analysis showed that the meropenem-resistant strain-specific recombination regions included the pbp1a and pbp2b regions. A detailed analysis of the composition of these genes indicated that resistance seems to be caused by pbp1a recombination. The pbp1a gene in meropenem-resistant isolates was identical to that in multidrug (including meropenem)-resistant serotype 19A-ST320 pneumococci, which have spread in the United States. The global spread of pneumococci of this lineage is noteworthy because serotype 15A is not included in the currently used 13-valent pneumococcal conjugate vaccine.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据